2/23
09:10 am
wve
Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Low
Report
Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/23
08:30 am
wve
Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Low
Report
Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
2/23
06:43 am
wve
Wave Life Sciences (WVE) Valuation Check After Regaining WVE-006 Rights And New Buy Analyst Coverage [Yahoo! Finance]
Low
Report
Wave Life Sciences (WVE) Valuation Check After Regaining WVE-006 Rights And New Buy Analyst Coverage [Yahoo! Finance]
2/19
08:30 am
wve
Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026
Low
Report
Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026
2/16
12:38 pm
wve
Wave Life Sciences (WVE) to Benefit From Optimism Surrounding Alpha-1 Antitrypsin Deficiency Program [Yahoo! Finance]
Medium
Report
Wave Life Sciences (WVE) to Benefit From Optimism Surrounding Alpha-1 Antitrypsin Deficiency Program [Yahoo! Finance]
2/12
09:46 am
wve
WAVE Life Sciences (NASDAQ:WVE) had its price target lowered by analysts at Wells Fargo & Company from $29.00 to $27.00. They now have an "overweight" rating on the stock.
Low
Report
WAVE Life Sciences (NASDAQ:WVE) had its price target lowered by analysts at Wells Fargo & Company from $29.00 to $27.00. They now have an "overweight" rating on the stock.
2/9
12:02 am
wve
The Bull Case For Wave Life Sciences (WVE) Could Change Following WVE-006 Rights Reversion And FDA Talks [Yahoo! Finance]
Low
Report
The Bull Case For Wave Life Sciences (WVE) Could Change Following WVE-006 Rights Reversion And FDA Talks [Yahoo! Finance]
2/8
05:36 pm
wve
Assessing Wave Life Sciences (WVE) Valuation After A 7x Three Year Total Return [Yahoo! Finance]
Low
Report
Assessing Wave Life Sciences (WVE) Valuation After A 7x Three Year Total Return [Yahoo! Finance]
2/7
03:48 am
wve
Wave Life Sciences (WVE) Regains Rights to Potential Rare Genetic Disorder Treatment [Yahoo! Finance]
Low
Report
Wave Life Sciences (WVE) Regains Rights to Potential Rare Genetic Disorder Treatment [Yahoo! Finance]
2/7
02:07 am
wve
WAVE Life Sciences (NASDAQ:WVE) was downgraded by analysts at
Wall Street
Low
Report
WAVE Life Sciences (NASDAQ:WVE) was downgraded by analysts at
Wall Street
2/5
10:00 am
wve
WAVE Life Sciences (NASDAQ:WVE) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $38.00 price target on the stock.
High
Report
WAVE Life Sciences (NASDAQ:WVE) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $38.00 price target on the stock.
2/5
09:41 am
wve
WAVE Life Sciences (NASDAQ:WVE) had its price target raised by analysts at Cantor Fitzgerald from $34.00 to $41.00. They now have an "overweight" rating on the stock.
Medium
Report
WAVE Life Sciences (NASDAQ:WVE) had its price target raised by analysts at Cantor Fitzgerald from $34.00 to $41.00. They now have an "overweight" rating on the stock.
2/3
12:51 pm
wve
Wave Life Sciences price target raised to $50 from $47 at Clear Street [Yahoo! Finance]
Low
Report
Wave Life Sciences price target raised to $50 from $47 at Clear Street [Yahoo! Finance]
2/3
08:15 am
wve
WAVE Life Sciences (NASDAQ:WVE) was given a new $43.00 price target on by analysts at Canaccord Genuity Group Inc..
Low
Report
WAVE Life Sciences (NASDAQ:WVE) was given a new $43.00 price target on by analysts at Canaccord Genuity Group Inc..
2/2
07:41 am
wve
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency [Yahoo! Finance]
Medium
Report
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency [Yahoo! Finance]
2/2
07:30 am
wve
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
Medium
Report
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
1/23
05:09 am
wve
WAVE Life Sciences (NASDAQ:WVE) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
WAVE Life Sciences (NASDAQ:WVE) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/19
01:53 am
wve
Should Wave's New Obesity Data and INHBE/ALK7 Focus Require Action From Wave Life Sciences (WVE) Investors? [Yahoo! Finance]
Low
Report
Should Wave's New Obesity Data and INHBE/ALK7 Focus Require Action From Wave Life Sciences (WVE) Investors? [Yahoo! Finance]
1/12
08:05 am
wve
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio [Yahoo! Finance]
Low
Report
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio [Yahoo! Finance]
1/12
07:30 am
wve
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio
Low
Report
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio
1/11
01:03 am
wve
WAVE Life Sciences (NASDAQ:WVE) was upgraded by analysts at
Wall Street Z
Low
Report
WAVE Life Sciences (NASDAQ:WVE) was upgraded by analysts at
Wall Street Z
1/5
08:30 am
wve
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
1/3
01:08 am
wve
WAVE Life Sciences (NASDAQ:WVE) was downgraded by analysts at
Wall Street
Medium
Report
WAVE Life Sciences (NASDAQ:WVE) was downgraded by analysts at
Wall Street
1/2
10:56 am
wve
Wave Life Sciences (WVE) Emerges as Obesity Treatment Contender, Oppenheimer Boosts Price Target [Yahoo! Finance]
Low
Report
Wave Life Sciences (WVE) Emerges as Obesity Treatment Contender, Oppenheimer Boosts Price Target [Yahoo! Finance]
1/1
07:15 am
wve
H.C. Wainwright Maintains A Buy Rating On Wave Life Sciences Ltd. (WVE) [Yahoo! Finance]
Medium
Report
H.C. Wainwright Maintains A Buy Rating On Wave Life Sciences Ltd. (WVE) [Yahoo! Finance]